Browse

The efficacy and safety of co-administration of fimasartan and rosuvastatin to patients with hypertension and dyslipidemia

Cited 7 time in Web of Science Cited 8 time in Scopus
Authors
Rhee, Moo-Yong; Ahn, Taehoon; Chang, Kiyuk; Chae, Shung Chull; Yang, Tae-Hyun; Shim, Wan Joo; Kang, Tae Soo; Ryu, Jae-Kean; Nah, Deuk-Young; Park, Tae-Ho; Chae, In-Ho; Park, Seung Woo; Lee, Hae-Young; Tahk, Seung-Jea; Yoon, Young Won; Shim, Chi Young; Shin, Dong-Gu; Seo, Hong Seog; Lee, Sung Yun; Kim, Doo Il; Kwan, Jun; Joo, Seung-Jae; Jeong, Myung Ho; Jeong, Jin-Ok; Sung, Ki Chul; Kim, Seok Yeon; Kim, Sang-Hyun; Chun, Kook-Jin; Oh, Dong Joo
Issue Date
2017-01-05
Publisher
BioMed Central
Citation
BMC Pharmacology and Toxicology, 18(1):2
Keywords
FimasartanRosuvastatinHypertensionHypercholesterolemia
Abstract
Background
Hypertension and dyslipidemia are major risk factors of cardiovascular disease (CVD) events. The objective of this study was to evaluate the efficacy and safety of the co-administration of fimasartan and rosuvastatin in patients with hypertension and hypercholesterolemia.

Methods
We conducted a randomized double-blind and parallel-group trial. Patients who met eligible criteria after 4 weeks of therapeutic life change were randomly assigned to the following groups.
1) co-administration of fimasartan 120 mg/rosuvastatin 20 mg (FMS/RSV), 2) fimasartan 120 mg (FMS) alone 3) rosuvastatin 20 mg (RSV) alone. Drugs were administered once daily for 8 weeks.

Results
Of 140 randomized patients, 135 for whom efficacy data were available were analyzed. After 8 weeks of treatment, the FMS/RSV treatment group showed greater reductions in sitting systolic (siSBP) and diastolic (siDBP) blood pressures than those in the group receiving RSV alone (both p < 0.001). Reductions in siSBP and siDBP were not significantly different between the FMS/RSV and FMS alone groups (p = 0.500 and p = 0.734, respectively). After 8 weeks of treatment, FMS/RSV treatment showed greater efficacy in percentage reduction of low-density lipoprotein cholesterol (LDL-C) level from baseline than that shown by FMS alone treatment (p < 0.001). The response rates of siSBP with FMS/RSV, FMS alone, and RSV alone treatments were 65.22, 55.56, and 34.09%, respectively (FMS/RSV vs. RSV, p = 0.006). The LDL-C goal attainment rates with FMS/RSV, RSV alone, and FMS alone treatments were 80.43%, 81.82%, and 15.56%, respectively (FMS/RSV vs. FMS, p < 0.001). Incidence of adverse drug reactions with FMS/RSV treatment was 8.33%, which was similar to those associated with FMS and RSV alone treatments.

Conclusion
This study demonstrated that the co-administration of fimasartan and rosuvastatin to patients with both hypertension and hypercholesterolemia was efficacious and safe.

Trial registration
ClinicalTrials.gov Identifier: NCT0216681. 16 June 2014
Language
English
URI
https://hdl.handle.net/10371/110103
DOI
https://doi.org/10.1186/s40360-016-0112-7
Files in This Item:
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Internal Medicine (내과학전공)Journal Papers (저널논문_내과학전공)
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse